Newport Beach, California, August 19, 2026
Renata Medical, a medical technology company focused on pediatric congenital heart disease (CHD), has closed a $25 million Series D financing round led by ARCHIMED, a global healthcare investment firm, with participation from existing investors. The financing is expected to support the company’s U.S. commercialization activities, international expansion, continued development of pediatric cardiovascular technologies, and clinical evidence generation for its Minima™ Stent System.
Funding Supports Minima™ Stent Expansion
Renata Medical said proceeds from the Series D financing will be used to expand commercialization of the Minima™ Stent System in the United States and support entry into international markets. The company also plans to advance its pipeline of pediatric-specific cardiovascular technologies and continue generating clinical evidence as adoption of Minima grows among congenital heart programs. The financing follows the commercial launch of Minima in 2024. According to Renata Medical, adoption of the technology has exceeded expectations since launch, supporting the company’s strategy of developing cardiovascular devices specifically for children rather than adapting technologies primarily designed for adults. The Series D investment from ARCHIMED provides additional capital for Renata’s next stage of growth as the company seeks to broaden access to its pediatric cardiovascular technology and establish a larger international presence.
Minima Stent Designed for Growing Children
The Minima™ Stent System is described by Renata Medical as the first balloon-expandable growth stent specifically designed for neonates, infants and young children with pulmonary artery stenosis or coarctation of the aorta. The device addresses a particular challenge in pediatric cardiovascular care, where patients continue to grow after implantation and may require interventions when conventional devices are not designed around pediatric growth. Renata Medical received FDA premarket approval for Minima in August 2024. In August 2025, the Centers for Medicare & Medicaid Services granted the device New Technology Add-on Payment (NTAP) designation, providing hospitals with additional reimbursement support for the technology. The company is developing Minima as part of a broader effort to address unmet needs in children with congenital heart defects. Pediatric patients can require specialized cardiovascular interventions throughout childhood, creating demand for devices that account for their anatomy, age and ongoing growth. According to Renata, continued clinical evidence generation will accompany the broader adoption of Minima across leading congenital heart programs worldwide.
Advertisement
ARCHIMED Investment Accelerates Pediatric MedTech
ARCHIMED’s investment reflects growing interest in specialized pediatric medical technology addressing significant clinical needs. The healthcare-focused investment firm brings experience across cardiovascular devices and other healthcare sectors, with operations spanning Europe, North America and Asia. André-Michel Ballester, Managing Partner at ARCHIMED and former CEO of LivaNova, said pediatric patients have historically been treated with devices developed primarily for adults, potentially resulting in repeat procedures when implants cannot accommodate growth. ARCHIMED said the Minima technology represents an opportunity to address this unmet need while supporting Renata Medical’s commercial expansion and future product development. Founded in 2019, Renata Medical focuses on creating, manufacturing and commercializing cardiovascular devices specifically designed for pediatric patients. The company’s strategy includes expanding its existing technology and developing a broader pipeline of purpose-built pediatric cardiovascular therapies. The newly secured $25 million Series D financing gives Renata additional resources to advance these objectives, including U.S. commercialization, international market entry and clinical evidence generation. As pediatric cardiovascular care continues to require highly specialized solutions, the company’s focus on growth-oriented devices could contribute to the development of more tailored treatment options for children with congenital heart disease.
Source: Renata Medical press relese
